Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Triple Negative Breast Neoplasms 1Neoplasms 1Lymphoma 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 344Cytarabine 281fludarabine phosphate 201Methotrexate 185Filgrastim 159Busulfan 147Etoposide 135Peripheral Blood Stem Cell Transplantation 133fludarabine 127Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 85Mycophenolic Acid 85Whole-Body Irradiation 80Melphalan 79Idarubicin 67Imatinib Mesylate 66Mercaptopurine 65Granulocyte Colony-Stimulating Factor 65Azacitidine 65Methylprednisolone 59Doxorubicin 58Prednisone 57Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Leukemia × eryaspase × Clear all
NCT01810705 2022-02-21

ENFORCE

ERYtech Pharma

Phase 2 Completed
123 enrolled 8 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT01910428 2018-07-05

L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL

ERYtech Pharma

Phase 1 Terminated
14 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡